Project Grant R01CA311058
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $677K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $537,531 on August 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized controlled clinical trial evaluating transcutaneous low-frequency vagal block (TLFVB) in patients with metastatic pancreatic ductal adenocarcinoma receiving frontline chemotherapy. The project will assess whether TLFVB can halt cachexia progression and improve associated phenotypes including weight...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $667,282 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test dissemination strategies for lung cancer screening education and counseling delivered through existing state tobacco quitlines. The project compares a low-touch strategy (text/email educational materials alone) against a high-touch strategy in which tobacco treatment specialists within...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $1.361 million on September 19, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a family-centered lifestyle intervention for Black prostate cancer survivors and their caregivers. The award funds a randomized controlled trial of "Together Stronger," a program targeting physical activity and healthy eating among Black prostate cancer survivors and their...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $747,660 on June 2, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the RADIANT trial, which builds evidence for a scalable remote patient monitoring and integrative medicine intervention delivered via telemedicine to reduce hospital readmissions in medical oncology patients discharged to home. The trial addresses the 12-week readmission rate for cancer patients, which ranges...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $663,818 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to assess the impact of early physiotherapy on lymphatic dysfunction in breast cancer survivorship through longitudinal measurement of lymphatic dysfunction using quantitative near-infrared fluorescence lymphatic imaging, evaluation of early physical rehabilitation with advanced pneumatic compression on lymphatic...
- The National Cancer Institute, within the Department of Health and Human Services, awarded $442,146 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a first-in-class clinical trial of natural killer cell therapy engineered to target intracellular antigens in acute myeloid leukemia and high-risk myelodysplastic syndromes. The funded work develops and tests cord blood-derived, off-the-shelf NK cells...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,458 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a digital intervention that uses patient portals to improve person-centered communication between cancer patients and oncology clinicians. The PERSON intervention comprises three automated, scalable components: a portal-enabled assessment tool (a 14-item questionnaire capturing patient information...
- The National Cancer Institute awarded MD Anderson Cancer Center a $1.5 million Cooperative Agreement on July 23, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop clinical-grade combinatorial new approach methodologies (NAMs) assays for colorectal cancer treatment decisions. The recipient will validate three core methodologies—in vitro micro-organospheres (MOSs), in silico DL-Reflect, and VirtualCellTherapy—using clinical samples and patient outcomes across...